| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1173 | 2021 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 889 | 2022 |
| Mapping the human genetic architecture of COVID-19 MEK Niemi, J Karjalainen, RG Liao, BM Neale, M Daly, A Ganna, ... Nature 600, 472-477, 2021 | 838* | 2021 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity EC Thomson, LE Rosen, JG Shepherd, R Spreafico, A da Silva Filipe, ... Cell 184 (5), 1171-1187. e20, 2021 | 597 | 2021 |
| SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway BJ Willett, J Grove, OA MacLean, C Wilkie, G De Lorenzo, W Furnon, ... Nature microbiology 7 (8), 1161-1179, 2022 | 555 | 2022 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 109292, 2021 | 466 | 2021 |
| Late Ebola virus relapse causing meningoencephalitis: a case report M Jacobs, A Rodger, DJ Bell, S Bhagani, I Cropley, A Filipe, RJ Gifford, ... The Lancet 388 (10043), 498-503, 2016 | 393 | 2016 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 374 | 2021 |
| Cationic liposomes for gene delivery S Simões, A Filipe, H Faneca, M Mano, N Penacho, N Düzgünes, ... Expert opinion on drug delivery 2 (2), 237-254, 2005 | 364 | 2005 |
| SARS-CoV-2 within-host diversity and transmission KA Lythgoe, M Hall, L Ferretti, M de Cesare, G MacIntyre-Cockett, ... Science 372 (6539), eabg0821, 2021 | 349 | 2021 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 341 | 2021 |
| Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins E Mastrobattista, GA Koning, L van Bloois, ACS Filipe, W Jiskoot, G Storm Journal of Biological Chemistry 277 (30), 27135-27143, 2002 | 295 | 2002 |
| Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil CL Donald, B Brennan, SL Cumberworth, VV Rezelj, JJ Clark, ... PLoS neglected tropical diseases 10 (10), e0005048, 2016 | 244 | 2016 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 241 | 2021 |
| A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research SJ Rihn, A Merits, S Bakshi, ML Turnbull, A Wickenhagen, AJT Alexander, ... PLoS biology 19 (2), e3001091, 2021 | 211 | 2021 |
| Cationic liposomes for gene delivery: from biophysics to biological applications MC de Lima, S Neves, A Filipe, N Duzgunes, S Simoes Current medicinal chemistry 10 (14), 1221-1231, 2003 | 203 | 2003 |
| An integrated national scale SARS-CoV-2 genomic surveillance network DM Aanensen, K Abudahab, A Adams, S Afifi, MT Alam, A Alderton, ... Elsevier, 0 | 186* | |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 165 | 2021 |
| In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2 AM Szemiel, A Merits, RJ Orton, OA MacLean, RM Pinto, A Wickenhagen, ... PLoS pathogens 17 (9), e1009929, 2021 | 147 | 2021 |
| Adeno-associated virus 2 infection in children with non-AE hepatitis A Ho, R Orton, R Tayler, P Asamaphan, L Tong, K Smollett, C Davis, ... medRxiv, 2022 | 144 | 2022 |
